{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T18:44:10Z","timestamp":1755801850994,"version":"3.44.0"},"reference-count":31,"publisher":"Weston Medical Publishing","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J of Opioid Management"],"abstract":"<jats:p>Despite the contribution of the \u03bc-agonist fentanyl to the United States\u2019s opiate overdose epidemic, no human studies specifically address the ability of extended-release preparations of the opiate antagonist naltrexone (NTX) to block fentanyl\u2019s life-threatening \u03bc-agonist-mediated respiratory depression. This paper presents three case histories of clinically necessary opiate challenges in opiate-abusing patients implanted with extended-release NTX (ER-NTX). It also reviews the sparse literature and is the first evidence that antagonist blood levels from ER-NTX preparations can completely block the lethal \u03bc-agonist effects of at least 1,000 mcg of intravenous fentanyl.<\/jats:p>","DOI":"10.5055\/jom.0949","type":"journal-article","created":{"date-parts":[[2025,8,20]],"date-time":"2025-08-20T19:34:41Z","timestamp":1755718481000},"page":"353-359","source":"Crossref","is-referenced-by-count":0,"title":["Fentanyl-blocking effects of extended-release naltrexone in humans: Three case reports"],"prefix":"10.5055","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5035-5833","authenticated-orcid":false,"given":"Colin","family":"Brewer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3008","published-online":{"date-parts":[[2025,8,1]]},"reference":[{"key":"96960","doi-asserted-by":"crossref","unstructured":"Gal TJ, DiFazio CA, Dixon R: Prolonged blockade of opioid effect with oral nalmefene. Clin Pharmacol Ther. 1986; 40(5): 537-542.","DOI":"10.1038\/clpt.1986.220"},{"key":"96961","doi-asserted-by":"crossref","unstructured":"Dean RL, Todtenkopf MS, Deaver DR, et al.: Overriding the blockade of antinociceptive actions of opioids in rats treated with extended-release naltrexone. Pharmacol Biochem Behav. 2008; 89(4): 515-522. DOI: 10.1016\/j.pbb.2008.02.006.","DOI":"10.1016\/j.pbb.2008.02.006"},{"key":"96962","doi-asserted-by":"crossref","unstructured":"Miller MW, Wild MA, Lance WR: Efficacy and safety of naltrexone hydrochloride for antagonizing carfentanil citrate immobilization in captive rocky Mountain elk (Cervus elaphus nelsoni). J Wildl Dis. 1996; 32(2): 234-239.","DOI":"10.7589\/0090-3558-32.2.234"},{"key":"96963","doi-asserted-by":"crossref","unstructured":"Benner JD, Cohen SM, Hollenbaugh JA, et al.: Fentanyl-induced respiratory depression in rodents is inhibited by bioabsorbable, subcutaneous naltrexone implants at 3.5 months. Addict Biol. 2023; 28(12): e13350. DOI: 10.1111\/adb.13350.","DOI":"10.1111\/adb.13350"},{"key":"96964","doi-asserted-by":"crossref","unstructured":"Joyner RL, Hollenbaugh JA, D'Aquila D, et al.: Bioabsorbable, subcutaneous naltrexone implants mitigate fentanyl-induced respiratory depression at 3 months\u2014A pilot study in male canines. Physiol Rep. 2024; 12(15): e16176. DOI: 10.14814\/phy2.16176.","DOI":"10.14814\/phy2.16176"},{"key":"96965","doi-asserted-by":"crossref","unstructured":"Foster J, Brewer C, Steele T: Naltrexone implants can completely prevent early (1-month) relapse after opiate detoxification: A pilot study of two cohorts totalling 101 patients with a note on naltrexone blood levels. Addict Biol. 2003; 8(2): 211-217. DOI: 10.1080\/1355621031000117446.","DOI":"10.1080\/1355621031000117446"},{"key":"96966","doi-asserted-by":"crossref","unstructured":"Olsen L, Christophersen AS, Frogopsahl G, et al.: Plasma concentrations during naltrexone implant treatment of opiatedependent patients. Br J Clin Pharmacol. 2004; 58(2): 219-222. DOI: 10.1111\/j.1365-2125.2004.02122.x.","DOI":"10.1111\/j.1365-2125.2004.02122.x"},{"key":"96967","doi-asserted-by":"crossref","unstructured":"Hulse GK, Arnold-Reed DE, O'Neil G, et al.: Achieving long-term continuous blood naltrexone and 6-beta-naltrexol coverage following sequential naltrexone implants. Addict Biol. 2004; 9: 67-72.","DOI":"10.1080\/13556210410001674112"},{"key":"96968","doi-asserted-by":"crossref","unstructured":"Hulse GK, Tait RJ: A pilot study to assess the impact of naltrexone implant on accidental opiate overdose in \u2018high-risk\u2019 adolescent heroin users. Addict Biol. 2003; 8(3): 337-342. DOI: 10.1080\/13556210310001602257.","DOI":"10.1080\/13556210310001602257"},{"key":"96969","doi-asserted-by":"crossref","unstructured":"Hulse GK, Low VH, Stalenberg V, et al.: Biodegradability of naltrexone-poly(DL) lactide implants in vivo assessed under ultrasound in humans. Addict Biol. 2008; 13(3-4): 364-372. DOI: 10.1111\/j.1369-1600.2007.00081.x.","DOI":"10.1111\/j.1369-1600.2007.00081.x"},{"key":"96970","doi-asserted-by":"crossref","unstructured":"Ngo HT, Tait RJ, Arnold-Reed DE, et al.: Mental health outcomes following naltrexone implant treatment for heroin-dependence. Prog Neuropsychopharmacol Biol Psychiatry. 2007; 31(3): 605-612. DOI: 10.1016\/j.pnpbp.2006.12.005.","DOI":"10.1016\/j.pnpbp.2006.12.005"},{"key":"96971","doi-asserted-by":"crossref","unstructured":"Brewer C, Streel E, Skinner M: Supervised Disulfiram\u2019s superior effectiveness in alcoholism treatment: Ethical, methodological, and psychological aspects. Alcohol Alcoholism. 2017; 52(2): 213-219. DOI: 10.1093\/alcalc\/agw093.","DOI":"10.1093\/alcalc\/agw093"},{"key":"96972","doi-asserted-by":"crossref","unstructured":"Brewer C, Krupitsky E: Chapter 226: Antagonists for the treatment of opioid dependence. In Encyclopaedia of Addictive Behaviors. Amsterdam: Elsevier, 2012.","DOI":"10.1016\/B978-0-12-398338-1.00045-2"},{"key":"96973","doi-asserted-by":"crossref","unstructured":"Gatch MB, Hill RD, Sundar M, et al.: Discriminative stimulus and antinociceptive effects of sixteen nitazene analogs in rodents. Neuropharmacology. 2025; 272: 110416. DOI: 10.1016\/j.neuropharm.2025.110416.","DOI":"10.1016\/j.neuropharm.2025.110416"},{"key":"96974","doi-asserted-by":"crossref","unstructured":"Phua CK, Wee A, Lim A, et al.: Fentanyl-induced chest wall rigidity syndrome in a routine bronchoscopy. Respir Med Case Rep. 2017; 20: 205-207. DOI: 10.1016\/j.rmcr.2017.02.012.","DOI":"10.1016\/j.rmcr.2017.02.012"},{"key":"96975","doi-asserted-by":"crossref","unstructured":"Zoorob R, Uptegrove L, Park BL: Case report of very-low-dose fentanyl causing fentanyl-induced chest wall rigidity. Cureus. 2023; 15(8): e43788. DOI: 10.7759\/cureus.43788.","DOI":"10.7759\/cureus.43788"},{"key":"96976","doi-asserted-by":"crossref","unstructured":"Somerville NJ, O\u2019Donnell J, Gladden RM, et al.: Characteristics of fentanyl overdose\u2014Massachusetts, 2014\u20132016. MMWR Morb Mortal Wkly Rep. 2017; 66: 382-386.","DOI":"10.15585\/mmwr.mm6614a2"},{"key":"96977","doi-asserted-by":"crossref","unstructured":"Kruptisky EM, Burakov AM, Tsoy MV, et al.: Overcoming opioid blockade from depot naltrexone (prodetoxon). Addiction. 2007; 102(7): 1164-1165. DOI: 10.1111\/j.1360-0443.2007.01817.x. Erratum in: Addiction. 2007; 102(8): 1334.","DOI":"10.1111\/j.1360-0443.2007.01817.x"},{"key":"96978","doi-asserted-by":"crossref","unstructured":"Brewer C: Serum naltrexone and 6-beta-naltrexol levels from naltrexone implants can block very large amounts of heroin: A report of two cases. Addict Biol. 2002; 7(3): 321-323. DOI: 10.1080\/13556210220139541.","DOI":"10.1080\/13556210220139541"},{"key":"96979","doi-asserted-by":"crossref","unstructured":"Hulse GK, Tait RJ, Comer SD, et al.: Reducing hospital presentations in opioid overdose in patients treated with sustained release naltrexone implants. Drug Alcohol Depend. 2005; 79: 351-357.","DOI":"10.1016\/j.drugalcdep.2005.02.009"},{"key":"96980","doi-asserted-by":"crossref","unstructured":"Kelty E, Hulse G: Examination of mortality rates in a retrospective cohort of patients treated with oral or implant naltrexone for problematic opiate use. Addiction. 2012; 107(10): 1817-1824. DOI: 10.1111\/j.1360-0443.2012.03910.x.","DOI":"10.1111\/j.1360-0443.2012.03910.x"},{"key":"96981","doi-asserted-by":"crossref","unstructured":"Strang J, McCambridge J, Best D, et al.: Loss of tolerance and overdose mortality after inpatient opiate detoxification: Follow up study. BMJ. 2003; 326(7396): 959-960. DOI: 10.1136\/bmj.326.7396.959.","DOI":"10.1136\/bmj.326.7396.959"},{"key":"96982","unstructured":"Blachly P, Casey D, Marcel L: Rapid detoxification from heroin and methadone using naloxone. A model for study of the treatment of the opiate abstinence syndrome. In Senay E, Shorty V, Alkesne H (eds.): Development in the Field of Drug Abuse. Cambridge, MA: Schenkman, 1975: 327-336."},{"key":"96983","doi-asserted-by":"crossref","unstructured":"Carre\u00f1o JE, Bobes J, Brewer C, et al.: 24-Hour opiate detoxification and antagonist induction at home the 'Asturian method': A report on 1368 procedures. Addict Biol. 2002; 7(2): 243-250. DOI: 10.1080\/135562102200120479.","DOI":"10.1080\/135562102200120479"},{"key":"96984","doi-asserted-by":"crossref","unstructured":"Arnold-Reed DE, Hulse GK: A comparison of rapid (opioid) detoxification with clonidine-assisted detoxification for heroin-dependent persons. J Opioid Manag. 2005; 1(1): 17-23. DOI: 10.5055\/jom.2005.0007.","DOI":"10.5055\/jom.2005.0007"},{"key":"96985","doi-asserted-by":"crossref","unstructured":"Brewer C, Williams J, Carre\u00f1o E, et al.: Unethical promotion of rapid opiate detoxification under anaesthesia (RODA). Lancet. 1998; 351: 218.","DOI":"10.1016\/S0140-6736(05)78171-X"},{"key":"96986","unstructured":"De Jong C: Subcutaneous naltrexone implants: A one-year follow-up study. In Paper presented at 10th Stapleford International Conference, Athens, Greece. 2011."},{"key":"96987","doi-asserted-by":"crossref","unstructured":"Newton-Howes G, Levack WM, McBride S, et al.: Nonphysiological mechanisms influencing disulfiram treatment of alcohol use disorder: A grounded theory study. Drug Alcohol Depend. 2016; 165: 126-131.","DOI":"10.1016\/j.drugalcdep.2016.05.027"},{"key":"96988","doi-asserted-by":"crossref","unstructured":"Krampe H, Stawicki S, Wagner T, et al.: Follow-up of 180 alcoholic patients for up to 7 years after outpatient treatment: Impact of alcohol deterrents on outcome. Alcohol Clin Exp Res. 2006; 30(1): 86-95. DOI: 10.1111\/j.1530-0277.2006.00013.x.","DOI":"10.1111\/j.1530-0277.2006.00013.x"},{"key":"96989","doi-asserted-by":"crossref","unstructured":"Brewer C, Streel E: Learning the language of abstinence in addiction treatment: Some similarities between relapse-prevention with disulfiram, naltrexone, and other pharmacological antagonists and intensive \"immersion\" methods of foreign language teaching. Subst Abus. 2003; 24(3): 157-173. DOI: 10.1080\/08897070309511545.","DOI":"10.1080\/08897070309511545"},{"key":"96990","doi-asserted-by":"crossref","unstructured":"Solli KK, Benth JS\u02c7, Digranes LCW, et al.: Changes in mental health during long-term treatment with extended-release naltrexone: A 3-year clinical study of opioid dependent individuals. Contemp Clin Trials. 2025; 152: 107861. DOI: 10.1016\/j.cct.2025.107861.","DOI":"10.1016\/j.cct.2025.107861"}],"container-title":["Journal of Opioid Management"],"original-title":[],"link":[{"URL":"https:\/\/wmpllc.org\/ojs\/index.php\/jom\/article\/download\/3892\/4177","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/wmpllc.org\/ojs\/index.php\/jom\/article\/download\/3892\/4177","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,20]],"date-time":"2025-08-20T19:34:49Z","timestamp":1755718489000},"score":1,"resource":{"primary":{"URL":"https:\/\/wmpllc.org\/ojs\/index.php\/jom\/article\/view\/3892"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,1]]},"references-count":31,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,8,20]]}},"URL":"https:\/\/doi.org\/10.5055\/jom.0949","relation":{},"ISSN":["1551-7489","1551-7489"],"issn-type":[{"type":"electronic","value":"1551-7489"},{"type":"print","value":"1551-7489"}],"subject":[],"published":{"date-parts":[[2025,8,1]]}}}